A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients

Inclusion Criteria: * Signed informed consent must be obtained prior to participation in the study History of migraine with or without aura for at least 12 months prior to screening 4. Migraine frequency: ≥ 4 and \< 15 migraine days per month on average across the 3 months prior to screening and confirmed during the baseline phase based on diary calculation * Headache frequency: \<15 headache days per month on average across the 3 months prior to screening and confirmed during the baseline phase based on diary calculation * Failure to 2 or more previous treatment categories locally indicated for migraine prophylaxis due to either lack of efficacy or poor tolerability Exclusion Criteria: * History of cluster headache or hemiplegic migraine headache * History of chronic pain disorders and neuropathic pain * History of head trauma or seizure or major psychiatric disorders or suicidal ideation/behavior at any time before screening * Currently, receiving any other prophylactic treatment for migraine and/or prohibited medications, non-pharmacologic interventions or devices (any substance, non-pharmacologic intervention or device acting at central nervous system), or less than 60 days or 5 half-lives prior to the start of the baseline period, during the baseline period, or treatment period * Exposure to botulinum toxin in the head and/or neck region within 4 months prior to the start of the baseline period, during the baseline period, or treatment period. * Taken the following for any indication in any month during the 2 months prior to the start of the baseline period: * Ergotamines or triptans on ≥ 10 days per month, or * Simple analgesics (non-steroidal anti-inflammatory drugs \[NSAIDs\], acetaminophen) on ≥ 15 days per month, or * Opioid- or butalbital-containing analgesics on ≥4 days per month. * Previous exposure to erenumab or exposure to any other prophylactic CGRP-targeted therapy (prior to and during the study) * History or evidence of any other unstable or clinically significant medical condition that in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion * Subject has any clinically significant vital sign, laboratory, or electrocardiogram (ECG) abnormality during screening that, in the opinion of the investigator, could pose a risk to subject safety or interfere with the study evaluation * Evidence of drug or alcohol abuse or dependence within 12 months prior to screening, based on medical records or patient self-report * Pregnant or breastfeeding * All the clinical conditions for which undergoing an MRI scan is contraindicated